atopic dermatitis

White Papers

Ensuring successful digital outreach and retention in atopic...

Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies.

News

Sidekick and Pfizer prep launch of DTx for atopic dermatitis

A long-running partnership between digital therapeutics (DTx) developer Si

News

Leo puts target on Dupixent in US as FDA clears tralokinumab

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab.

News

Pharma group will develop 'digital endpoint' for atopic derm...

The development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium of pharma companies has just identified a new one for atopic dermatitis.

News

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it

News

Pfizer gets first approval, in UK, for Xeljanz follow-up Cib...

Pfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Ensuring successful digital outreach and retention in atopic...

Sidekick and Pfizer prep launch of DTx for atopic dermatitis

Leo puts target on Dupixent in US as FDA clears tralokinumab

Pharma group will develop 'digital endpoint' for atopic derm...

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Pfizer gets first approval, in UK, for Xeljanz follow-up Cib...

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

atopic dermatitis

Editor's Picks